Akari Therapeutics completes $3.8M notes financing

Akari Therapeutics, Plc reports that it has completed its previously disclosed August 2025 unsecured promissory notes financing.

Rhea-AI Filing Summary

Akari Therapeutics, Plc reports that it has completed its previously disclosed August 2025 unsecured promissory notes financing. The company had agreed to sell notes with a 20% original issue discount for an aggregate purchase price of $3 million, resulting in a total principal amount of approximately $3.8 million.

On September 26, 2025, Akari closed the final tranche of this private placement, issuing $312,500 in aggregate principal amount of August 2025 Notes for a purchase price of $250,000. After this closing, the full approximate $3.8 million principal amount of August 2025 Notes has been issued to investors.

Insights

Capital structure analyst

Akari completes $3M discounted note financing, fully issuing $3.8M principal.

Akari Therapeutics, Plc has now fully closed its August 2025 unsecured promissory note financing. The company placed notes for an aggregate purchase price of $3 million, structured with a 20% original issue discount, which results in an aggregate principal amount of approximately $3.8 million owed to investors.

The final tranche closed on September 26, 2025, when Akari issued $312,500 aggregate principal amount of notes for a purchase price of $250,000. This confirms that the entire targeted principal amount from the August 2025 Notes Offering is now outstanding, giving the company additional funding while increasing its unsecured debt obligations.

Subsequent disclosures in future company filings may provide more detail on the notes’ maturity, interest terms, and how the proceeds support operations or strategic initiatives, which will shape the long‑term impact on Akari’s balance sheet.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

What did Akari Therapeutics (AKTX) announce in this 8-K?

Akari Therapeutics, Plc announced that it has closed the final tranche of its August 2025 unsecured promissory notes private placement and fully issued approximately $3.8 million in principal amount of notes.

How much did Akari Therapeutics (AKTX) raise in the August 2025 Notes Offering?

Akari agreed to sell August 2025 Notes for an aggregate purchase price of $3 million, which, with a 20% original issue discount, corresponds to an aggregate principal amount of approximately $3.8 million.

What were the terms of the final tranche of Akari’s August 2025 Notes Offering?

In the final tranche closed on September 26, 2025, Akari issued $312,500 aggregate principal amount of August 2025 Notes for an aggregate purchase price of $250,000.

What is the original issue discount on Akari Therapeutics’ August 2025 Notes?

The August 2025 Notes were issued with a 20% original issuance discount, meaning the principal amount of the notes is higher than the cash purchase price paid by investors.

Are Akari Therapeutics’ August 2025 Notes secured or unsecured?

The filing states that the August 2025 Notes issued by Akari Therapeutics are unsecured promissory notes.

Has Akari fully issued all notes related to the August 2025 Notes Offering?

Yes. Following the September 26, 2025 closing, Akari has issued an aggregate of approximately $3.8 million principal amount of August 2025 Notes, completing the offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/29/2025 - 05:00 PM Learn about SEC filing dates

false 0001541157 0001541157 2025-09-26 2025-09-26 0001541157 AKTX:AmericanDepositorySharesEachRepresenting2000OrdinarySharesMember 2025-09-26 2025-09-26 0001541157 AKTX:OrdinarySharesParValue0.0001PerShareMember 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2025

AKARI THERAPEUTICS, PLC

(Exact Name of Registrant as Specified in Charter)

England and Wales		001-36288		98-1034922
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

22 Boston Wharf Road FL 7

Boston, MA 02210

(Address, including zip code, of Principal Executive Offices)

Registrant’s telephone number, including area code: (929) 274-7510

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered
American Depository Shares, each representing 2000 Ordinary Shares		AKTX		The Nasdaq Stock Market LLC
Ordinary Shares, par value $0.0001 per share*		N/A		The Nasdaq Stock Market LLC

*Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

Closing of August 2025 Notes Offering 

As previously reported by the Company, on August 1, 2025, the Company entered into various note purchase agreements (the “Notes Purchase Agreements”) with certain investors (the “August 2025 Note Investors”), pursuant to which the Company agreed to issue unsecured promissory notes with a 20% original issuance discount (each a “August 2025 Note” and together, the “August 2025 Notes”) in a private placement (the “August 2025 Notes Offering”) for an aggregate purchase price of $3 million. The aggregate principal amount of the August 2025 Notes issuable is approximately $3.8 million.

On September 26, 2025, the Company closed on the final tranche of the August 2025 Notes Offering, issuing $312,500 aggregate principal amount of August 2025 Notes for an aggregate purchase price of $250,000. Following this closing, the Company has issued an aggregate of approximately $3.8 million principal amount of August 2025 Notes.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Akari Therapeutics, Plc
Date: September 29, 2025	By:	/s/ Torsten Hombeck
	Name:	Torsten Hombeck
	Title:	Chief Financial Officer